Managed Care Margin Recovery And Healthcare Benefits Will Shape Industry Prospects

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

18 Jul 24

Updated

09 Dec 25

Views

1k

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

75.2%

7D

-2.1%

Loading

1Y

75.2%

7D

-2.1%

You can edit this narrative until Dec 10 1:10 PM. Then, changes will post as Updates.

Author's Valuation

US$92.4415.9% undervalued

AnalystConsensusTarget Fair Value

Shared on 09 Dec 25

Fair value Increased 1.05%

CVS: Medicare Advantage Margin Recovery Will Drive Earnings Momentum From 2026

The analyst price target for CVS Health has edged higher by about $1 to approximately $92, as analysts point to resilient earnings, improving visibility in Medicare Advantage margins, and a solid Q3 performance as support for modestly stronger long term valuation assumptions. Analyst Commentary Research updates highlight a generally constructive view on CVS Health, with multiple firms lifting price targets and emphasizing improved earnings visibility and margin recovery potential over the medium term.

Shared on 25 Nov 25

Fair value Decreased 0.044%

CVS: Margin Recovery in Medicare Advantage Will Drive Earnings Momentum Through 2026

The analyst price target for CVS Health has been revised slightly lower from $91.52 to $91.48. Analysts point to a mixed quarterly report and evolving expectations around Medicare Advantage and earnings visibility as factors behind the update.

Shared on 08 Nov 25

Fair value Increased 6.17%

CVS: Earnings Momentum Will Drive Performance as Regulatory Shifts Unfold

Analysts have raised their fair value estimate for CVS Health to $91.52 from $86.20. This adjustment is due to improved earnings visibility and continued momentum following solid quarterly results.

Shared on 25 Oct 25

Fair value Increased 2.87%

Analysts have raised their fair value estimate for CVS Health to $86.20. This modest increase is supported by greater earnings visibility and expectations for margin recovery in the managed care sector.

Shared on 10 Oct 25

Fair value Increased 2.09%

Analysts have raised their price target for CVS Health, increasing it by nearly $2 to approximately $84 per share. They cite improved earnings visibility and strengthening fundamentals in the healthcare sector as key reasons for the change.

Shared on 04 Sep 25

Fair value Increased 0.61%

Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.

Shared on 07 May 25

Fair value Increased 6.77%

Shared on 30 Apr 25

Fair value Decreased 0.78%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Increased 4.83%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 0.36%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 0.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 0.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Decreased 8.86%

AnalystConsensusTarget has increased revenue growth from 4.7% to 5.2% and increased future PE multiple from 12.6x to 13.9x.

AnalystConsensusTarget Fair Value

US$92.44

15.9% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

4.24%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.30%

Calculation

US$9.11b

Earnings '28

x

16.25x

PE Ratio '28

=

US$148.07b

Market Cap '28

US$148.07b

Market Cap '28

/

1.30b

No. shares '28

=

US$114.28

Share Price '28

US$114.28 Share Price '28

Discounted to 2025 @ 7.35% p.a.

=

US$92.39

Fair Value '25